Issue Date: May 28, 2012
It says a lot about the maturity of biocatalysis as a synthetic tool that four major drugs—Pfizer’s Lipitor and Lyrica, and Merck & Co.’s Singulair and Januvia—are manufactured using enzymatic steps.
“From a technology point of view, it is now fully recognized that biotransformations can be commercialized,” says Junhua (Alex) Tao, a chemist who once headed a Pfizer biotransformations group and now runs two enzyme-related firms in China.
Although many drug and fine . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society